All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Adoptive immunotherapy using T cells expressing chimeric antigen receptors (CARs) has produced remarkable clinical outcomes. However, much of the mechanisms of action, such as the development of memory responses and sources of immune cytokines, remain elusive largely due to the challenge of characterizing human CAR T cell function in vivo. Creative Biolabs has established a syngeneic mouse model with a functional mouse immune system and genetically-matched (autologous) Ovarian cancer that permits modeling of AXL-targeted CAR T cell therapy in immunocompetent hosts without allogeneic immune responses. Our anti-AXL CAR T cells are prepared from freshly isolated T lymphocytes in a syngeneic mouse model, followed by ex vivo transduction with anti-AXL CAR lentiviral particles and amplification process to generate CAR T cells. These syngeneic mouse model-derived CAR-T cells offer many advantages including permitting the evaluation of antitumor responses in immunocompetent murine hosts, testing human CAR-T constructs against human primary malignance, and preclinical evaluation of CAR T cell therapies.
There are currently no customer reviews or questions for Anti-AXL (lgG1-AXL-733) h(CD28-CD3ζ) CAR-T Cells [Mouse CAR-T Cells] (MCAR-P972). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION